InspireMD (NYSE:NSPR) Research Coverage Started at StockNews.com

Analysts at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research note issued on Tuesday. The firm set a “sell” rating on the stock.

InspireMD Stock Performance

NSPR stock opened at $2.21 on Tuesday. The company has a market capitalization of $51.85 million, a PE ratio of -2.05 and a beta of 0.83. InspireMD has a one year low of $0.96 and a one year high of $3.85. The company’s 50 day moving average price is $2.47 and its two-hundred day moving average price is $2.73.

InspireMD (NYSE:NSPR) last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.04. InspireMD had a negative net margin of 320.97% and a negative return on equity of 55.71%. The firm had revenue of $1.76 million for the quarter, compared to the consensus estimate of $1.65 million. During the same period last year, the firm posted ($0.60) earnings per share. On average, research analysts predict that InspireMD will post -0.61 EPS for the current year.

Institutional Trading of InspireMD

Several large investors have recently added to or reduced their stakes in the stock. McKinley Carter Wealth Services Inc. bought a new stake in InspireMD in the fourth quarter valued at $28,000. Renaissance Technologies LLC bought a new stake in InspireMD in the second quarter valued at $36,000. Avestar Capital LLC bought a new stake in InspireMD in the third quarter valued at $65,000. Northern Trust Corp bought a new stake in InspireMD in the fourth quarter valued at $80,000. Finally, Nantahala Capital Management LLC boosted its holdings in InspireMD by 16.9% in the fourth quarter. Nantahala Capital Management LLC now owns 2,066,456 shares of the company’s stock valued at $5,807,000 after acquiring an additional 298,406 shares in the last quarter. Institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem lesions.